Drug intelligence / Profile preview

mitopodozide

Development stage: Discontinued
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Mitopodozide is an antineoplastic agent that was investigated as a potential chemotherapeutic drug. It is a derivative of podophyllotoxin and structurally related to etoposide and teniposide. Mitopodozide acts as a topoisomerase II inhibitor, thereby interfering with DNA synthesis and cell division. It was investigated primarily for use in cancer therapy. There is very limited clinical or commercial information available, and it has not reached widespread approval or use.

Brand names: mitopodozide
Other names: mitopodozide

Targets

TOP2A (DNA topoisomerase II)TUBB4A (β-tubulin 4A)

Beyond the preview

Go deeper on mitopodozide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mitopodozide.

Explore the full profile